JP6648040B2 - がん治療のための併用療法としてのエリブリン及びポリ（ａｄｐリボース）ポリメラーゼ（ｐａｒｐ）阻害剤の使用 - Google Patents

がん治療のための併用療法としてのエリブリン及びポリ（ａｄｐリボース）ポリメラーゼ（ｐａｒｐ）阻害剤の使用 Download PDF

Info

Publication number
JP6648040B2
JP6648040B2 JP2016569606A JP2016569606A JP6648040B2 JP 6648040 B2 JP6648040 B2 JP 6648040B2 JP 2016569606 A JP2016569606 A JP 2016569606A JP 2016569606 A JP2016569606 A JP 2016569606A JP 6648040 B2 JP6648040 B2 JP 6648040B2
Authority
JP
Japan
Prior art keywords
cancer
pharmaceutical composition
pharmaceutically acceptable
acceptable salt
eribulin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2016569606A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017516784A5 (https=
JP2017516784A (ja
Inventor
デービッド コックス，
デービッド コックス，
アルトン クレマー，
アルトン クレマー，
シャロン マクゴニガル，
シャロン マクゴニガル，
ジャイ ウー，
ジャイ ウー，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eisai R&D Management Co Ltd
Original Assignee
Eisai R&D Management Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Management Co Ltd filed Critical Eisai R&D Management Co Ltd
Publication of JP2017516784A publication Critical patent/JP2017516784A/ja
Publication of JP2017516784A5 publication Critical patent/JP2017516784A5/ja
Application granted granted Critical
Publication of JP6648040B2 publication Critical patent/JP6648040B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2016569606A 2014-05-28 2015-05-28 がん治療のための併用療法としてのエリブリン及びポリ（ａｄｐリボース）ポリメラーゼ（ｐａｒｐ）阻害剤の使用 Active JP6648040B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201462003798P 2014-05-28 2014-05-28
US62/003,798 2014-05-28
US201462088200P 2014-12-05 2014-12-05
US62/088,200 2014-12-05
PCT/US2015/032990 WO2015184145A1 (en) 2014-05-28 2015-05-28 Use of eribulin and poly (adp ribose) polymerase (parp) inhibitors as combination therapy for the treatment of cancer

Publications (3)

Publication Number Publication Date
JP2017516784A JP2017516784A (ja) 2017-06-22
JP2017516784A5 JP2017516784A5 (https=) 2018-07-05
JP6648040B2 true JP6648040B2 (ja) 2020-02-14

Family

ID=54699806

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016569606A Active JP6648040B2 (ja) 2014-05-28 2015-05-28 がん治療のための併用療法としてのエリブリン及びポリ（ａｄｐリボース）ポリメラーゼ（ｐａｒｐ）阻害剤の使用

Country Status (4)

Country Link
US (1) US10238630B2 (https=)
EP (1) EP3148336B1 (https=)
JP (1) JP6648040B2 (https=)
WO (1) WO2015184145A1 (https=)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2522663T1 (sl) 2004-06-03 2015-08-31 Eisai R&D Management Co., Ltd. Vmesne spojine za pripravo halihondrina B
CN102369008B (zh) 2009-03-30 2014-10-29 卫材R&D管理有限公司 脂质体组合物
BR112015029386B1 (pt) 2013-06-26 2023-11-14 Eisai R&D Management Co., Ltd. Uso de eribulina e lenvatinibe como terapia de combinação e kit
ITUB20159206A1 (it) * 2015-12-22 2017-06-22 Olon Spa Forme cristalline e amorfe di olaparib
WO2017188350A1 (ja) * 2016-04-28 2017-11-02 エーザイ・アール・アンド・ディー・マネジメント株式会社 腫瘍の成長を抑制する方法
JP7025416B2 (ja) 2016-06-06 2022-02-24 ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド 好中球減少症を低減させるための組成物および方法
SG11201811564QA (en) 2016-06-29 2019-01-30 Tesaro Inc Methods of treating ovarian cancer
WO2018129381A1 (en) 2017-01-06 2018-07-12 Beyondspring Pharmaceuticals, Inc. Tubulin binding compounds and therapeutic use thereof
BR112019015974A2 (pt) 2017-02-01 2020-03-31 Beyondspring Pharmaceuticals, Inc. Método para reduzir neutropenia
CN110475475A (zh) * 2017-02-06 2019-11-19 希望之城 癌症的治疗
CN110944638A (zh) 2017-03-27 2020-03-31 特沙诺有限公司 尼拉帕尼组合物
TW202444417A (zh) 2017-05-09 2024-11-16 美商提薩羅有限公司 治療癌症的組合療法
KR20200005662A (ko) 2017-05-18 2020-01-15 테사로, 인코포레이티드 암을 치료하기 위한 조합 요법
CN107098862A (zh) * 2017-06-05 2017-08-29 山东裕欣药业有限公司 一种奥拉帕尼二水合物及其制备方法
TWI843707B (zh) 2017-09-26 2024-06-01 美商提薩羅有限公司 尼拉帕尼（ｎｉｒａｐａｒｉｂ）調配物
MX2020003770A (es) 2017-09-30 2020-07-29 Tesaro Inc Terapias de combinacion para tratar cancer.
EA202090655A1 (ru) 2017-10-06 2020-12-07 Тесаро, Инк. Комбинированные терапевтические средства и их применение
WO2019097073A1 (en) 2017-11-20 2019-05-23 Basilea Pharmaceutica International AG Pharmaceutical combinations for use in the treatment of neoplastic diseases
CN111918667A (zh) * 2018-02-05 2020-11-10 特沙诺有限公司 儿科尼拉帕尼配制剂和儿科治疗方法
EP4552696A3 (en) * 2018-05-15 2025-11-05 Allarity Therapeutics Europe ApS Methods for predicting drug responsiveness in cancer patients
WO2020142583A1 (en) * 2019-01-04 2020-07-09 Actinium Pharmaceuticals, Inc. Methods for treating cancer using combinations of parp inhibitors and antibody radioconjugates
US12036204B2 (en) 2019-07-26 2024-07-16 Eisai R&D Management Co., Ltd. Pharmaceutical composition for treating tumor
US11083705B2 (en) 2019-07-26 2021-08-10 Eisai R&D Management Co., Ltd. Pharmaceutical composition for treating tumor
TW202228693A (zh) * 2020-10-08 2022-08-01 瑞典商阿斯特捷利康公司 用於治療癌症之組合療法
CA3215047A1 (en) 2021-04-09 2022-10-13 Lan Huang Therapeutic compositions and methods for treating tumors
WO2022217060A1 (en) * 2021-04-09 2022-10-13 Cardiff Oncology, Inc. Cancer treatment using parp inhibitors and plk1 inhibitors
WO2024054898A1 (en) * 2022-09-08 2024-03-14 Cardiff Oncology, Inc. Onvansertib and parp inhibitor combination
CA3267429A1 (en) 2022-09-11 2024-03-14 Cardiff Oncology, Inc. PLK1 INHIBITOR IN COMBINATION WITH ANTI-ANGIOGENICS FOR THE TREATMENT OF METASTATIC CANCER
WO2024137738A1 (en) * 2022-12-22 2024-06-27 The Board Of Regents Of The University Of Oklahoma Combinations of poly (adp-ribose) polymerase (parp) inhibitors and heteroarotinoids and methods of use as cancer treatments
CN121127241A (zh) * 2023-03-10 2025-12-12 万春药业公司 肿瘤联合治疗及使用方法
WO2025106586A1 (en) * 2023-11-13 2025-05-22 Luxvitae Therapeutics Inc. Macrocyclic ketone compounds and applications thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6653341B1 (en) * 1998-06-17 2003-11-25 Eisai Co., Ltd. Methods and compositions for use in treating cancer
ES2504690T3 (es) * 2007-10-03 2014-10-08 Eisai Inc. Compuestos inhibidores de PARP, composiciones y métodos de uso
EP2686441B1 (en) * 2011-03-18 2019-05-08 Eisai R&D Management Co., Ltd. Methods and uses for predicting response to eribulin
CA2843417C (en) * 2011-07-29 2018-08-21 Medivation Prostate Therapeutics, Inc. Treatment of breast cancer

Also Published As

Publication number Publication date
EP3148336A1 (en) 2017-04-05
WO2015184145A8 (en) 2016-02-04
US20170100368A1 (en) 2017-04-13
EP3148336B1 (en) 2019-10-02
EP3148336A4 (en) 2017-12-13
WO2015184145A1 (en) 2015-12-03
US10238630B2 (en) 2019-03-26
JP2017516784A (ja) 2017-06-22

Similar Documents

Publication Publication Date Title
JP6648040B2 (ja) がん治療のための併用療法としてのエリブリン及びポリ（ａｄｐリボース）ポリメラーゼ（ｐａｒｐ）阻害剤の使用
EP3066101B1 (en) Combination therapy for cancer using bromodomain and extra-terminal (bet) protein inhibitors
CN105338977B (zh) 艾日布林和乐伐替尼作为治疗癌症的联合疗法的用途
CN106860870B (zh) 抗肿瘤生物碱的联合治疗
AU2008254273B2 (en) Methods for using vasopressin antagonists with anthracycline chemotherapy agents to reduce cardiotoxicity and/or improve survival
AU2016309002A1 (en) Combination therapy using liposomal irinotecan and a PARP inhibitor for cancer treatment
EP3148526B1 (en) Use of eribulin in the treatment of cancer
TW202521120A (zh) 藥物組合物及其應用
HUP0302130A2 (hu) Kombinációs gyógyszerkészítmény és eljárás az előállításukra
CA3080644A1 (en) Use of parp inhibitor in treating chemotherapy-resistant ovarian cancer or breast cancer
JP2019511529A (ja) がんの処置において使用するための、Ｎｏｔｃｈ阻害剤およびＰＩ３Ｋ／ｍＴＯＲ阻害剤を用いた併用療法
MX2013013014A (es) Metodo para el tratamiento de tumores solidos avanzados.
AU2018234903B2 (en) Combination therapies for the treatment of breast cancer
CN106029070A (zh) 艾日布林和mTOR抑制剂作为治疗癌症的联合疗法的用途
WO2016081773A2 (en) Combination cancer therapy with c-met inhibitors and synthetic oligonucleotides
CN105283178A (zh) 用于治疗癌症的包含mps-1激酶抑制剂和有丝分裂抑制剂的组合
CN120529906A (zh) 用于治疗癌症的组合疗法
CN116672345A (zh) Parp抑制剂和细胞毒性剂的联合产品及其用途
EP4640218A1 (en) Use of sultam compound in treating biliary tract cancer
AU2024343230A1 (en) Combination of a wee1 inhibitor and a pkmyt1 inhibitor
CN118019537A (zh) Shp2抑制剂联合egfr-tki治疗和预防肿瘤疾病的医药用途
HK40026959A (en) Treatment of cancer with a combination of radiation, cerium oxide nanoparticles, and a chemotherapeutic agent
Price et al. 380 Phase I trial of OXi4503: positron emission tomography (PET) analysis shows early effects on tumour perfusion that predict metabolic response
HK1227400A1 (en) Combination therapy for cancer using bromodomain and extra-terminal (bet) protein inhibitors
JP2009500416A (ja) カリケアマイシン−抗体複合体をゾスキダルと組み合わせて用いる癌患者の処置

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180525

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180525

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190423

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190621

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20190813

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191105

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20191105

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20191122

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20191217

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20200115

R150 Certificate of patent or registration of utility model

Ref document number: 6648040

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250